BRAF^V600E基因突变和甲状腺乳头状癌临床病理特征关联性的Meta分析

Association of BRAFV600E mutation with clinical pathological features in papillary thyroid carcinoma：meta-analysis

目的 探索甲状腺乳头状癌中BRAFV600E基因突变和病理特征的关联性.方法 检索Medline、PubMed、Web of Science等数据库收集相关文献,应用Meta分析计算比值比（odds ratio,OR）及95％可信区间（confident intervel,CI）.结果 共有52篇相关文献纳入研究,12 029例甲状腺乳头状癌患者中BRAFV600E突变率为57.85％.结果显示：在甲状腺乳头状癌中,BRAFV600E基因突变和以下病理特征有关联性：病理分期（OR=1.89,95％ CI为1.58～ 2.27）、淋巴结转移（OR=1.74,95％ CI为1.42 ～2.14）、多灶性（OR=1.25,95％ CI为1.07～ 1.46）、疾病复发（OR=2.26,95％ CI为1.25～4.09）.在亚洲人群中BRAFV600E基因突变和以下病理特征有关联性：病理分期（OR=1.56,95％ CI为1.24 ～1.96）、淋巴结转移（OR=1.57,95％CI为1.25～ 1.99）.在欧洲人群中BRAFV600E基因突变和以下病理特征有关联性：病理分期（OR=2.63,95％ CI为2.10～3.30）、淋巴结转移（OR=1.97,95％CI为1.19～ 3.25）、多灶性（OR=1.35,95％CI为1.01～ 1.80）.结论 病理分期、淋巴结转移、多灶性、疾病复发与BRAFV600E突变有关联性.

Objective To evaluate the association between BRAF600E mutation and pathological features in papillary thyroid carcinoma （PTC）.Methods The raleted studies were searched through Medline,PubMed,and Web of Science,and meta-analysis was used to calculate the OR and 95% CI of the study results.Results A total of 52 studies including 12 029 PTC patients was identified.The prevalence of BRAFV600EE mutation in PTC was 57.85%.There was a closed association between the BRAFV600E mutation and pathological features,including advanced TNM stage （OR =1.89,95% CI 1.58-2.27）,lymph node metastasis （OR =1.74,95% CI 1.42-2.14）,multifocality （OR =1.25,95% CI 1.07-1.46）,and recurrence （OR =2.26,95% CI 1.25-4.09） of PTC.For Asians with PTC,the association between the BRAFV600E mutation and pathological features was indicated for advanced TNM stage（OR =1.56,95% CI 1.24-1.96） and lymph node metastasis（OR =1.57,95% CI 1.25-1.99）.For Europeans with PTC,the association between the BRAFV600E mutation and pathological features was indicated for advanced TNM stage （OR =2.63,95% CI 2.10-3.30）,lymph node metastasis（OR =1.97,95% CI 1.19-3.25）,and multifocality （OR =1.35,95% CI 1.01-1.80）.Conclusion There were associations between the BRAFV600EE mutation and advanced TNM stage,lymph node metastasis,multifocality,and recurrence of PTC.